Mandate

Vinge advises Smart Eye in a directed new share issue of MSEK 200

May 22, 2019

Vinge has advised Smart Eye AB (Nasdaq First North) on a directed new share issue that provides Smart Eye with approximately MSEK 200.

The subscription price, i.e. SEK 101.50, has been determined by an accelerated book‑building procedure corresponding to a discount of 1.6 per cent compared to the closing price on Nasdaq First North on 21 May 2019. Första AP‑fonden becomes a new major shareholder in the company after having been allotted more than half of the shares in the new issue and thereby becomes the third largest owner with 6.6 per cent of the shares and votes. In total, five major Nordic institutions were allotted approximately 75 per cent of the shares in the new share issue. The purpose of the new share issue is to finance the continued development of the business and an expanded offer towards the Chinese market. Carnegie Investment Bank has acted as sole bookrunner.

Vinge’s team has primarily consisted of responsible partner Anders Strid together with Wibeke Sorling and Edin Agic (Capital Markets), Gu Qun (China Practice), Alexander Lindeberg (IP), Victor Ericsson (Tax) as well as company assistant Camilla Andersson.

 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025